Experience

Resalis Therapeutics Srl

• Chief Executive Officer e Amministratore Delegato

  • Oct 2022 - Present

  Tackling metabolic disorders with non-coding RNAs. Tackling metabolic disorders with non-coding RNAs.



Italian Angels for Growth

• Business Angel

  • Jan 2020 - Present

  Lead Investor for IAG in: - Pep-Therapy (https://pep-therapy.com), Paris, Île-de-France, France, since Mar 2021 Developing and clinically testing a penetrating peptide showing great efficacy and tolerability in treating triple negative breast cancer and ovarian cancer - Neophore (https://www.neophore.com), Altrincham, Cheshire, United Kingdom, since Sep. 2021 Targeting the dynamics of cancer neoantigen evolution through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies - Nanoligent (http://www.nanoligent.com) Barcelona. Spain Using state-of-the-art protein engineering and nanobiotechnology to develop protein conjugates organized as nanoparticles and capable of targeting specific biological systems. Precision medicine aiming high therapeutic index and low side effects for oncology Show less



Novartis Italia

• Italy
• Pharmaceutical Manufacturing
• 200 - 300 Employee

• Head of Immunology Franchise; also Head of Respiratory & Allergy Franchise

  • Jan 2022 - Oct 2022

  Responsible of the portfolio in the areas of Immunology, Transplants, Dermatology, Rare Diseases on top of the areas of Respiratory and Allergy

• Head of Respiratory & Allergy Franchise

  • Jan 2019 - Oct 2022

  Responsible for Novartis portfolio in the areas of Asthma, Food Allergy, COPD, Urticaria, Nasal Polyps, Diabetes

• Sales and Marketing Head Rheumatology (Cosentyx)

  • Nov 2017 - Dec 2018

  Launched Cosentyx in Rheumatology in Italy



Shire

• Japan
• Biotechnology Research
• 700 & Above Employee

• Business Unit Head - Genetic Diseases

  • Dec 2015 - Oct 2017

  Leading the GD BU with drugs for Fabry, Gaucher and Hunter rare diseases Leading the GD BU with drugs for Fabry, Gaucher and Hunter rare diseases



Pfizer

• Events Services
• 1 - 100 Employee

• Marketing Head Oncology and Hematology Italy

  • May 2015 - Nov 2015

  Head of the marketing team responsible for six brands in multiple areas of Oncology and Hematology

• European Director Inflammation Strategy and Business Models

  • Oct 2013 - Apr 2015

  Strategy and actionability for ENBREL LOE and Biosimilars

• European Sr Brand Manager Inflammation

  • Nov 2010 - Sep 2013

  Implementation of key Specialty Care projectsStrategic Brand development for the auto-immune disease biologic drug ENBRELWinner of 2012 Pfizer Specialty Care Star Performance Global Award



Merck Group

• Germany
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Global Brand Leader Oncology

  • Jan 2010 - Oct 2010

  - Strategic Marketing development for the Oncology biologic drug ERBITUX

• Marketing Manager Oncology

  • Apr 2008 - Dec 2009

  Marketing and Business development for the Oncology biologic drug ERBITUX

• Product Manager Oncology

  • Jan 2006 - Mar 2008

  - Marketing development for the Oncology blockbuster brand ERBITUX and for UFT



Menarini

• Singapore
• Pharmaceutical Manufacturing
• 300 - 400 Employee

• Product Specialist Diabetology

  • Jan 2005 - Dec 2005

  Product Specialist in Diabetes Centers in Lombardia for self-testing devices GLUCOCARD and GLUCOMAN Product Specialist in Diabetes Centers in Lombardia for self-testing devices GLUCOCARD and GLUCOMAN



Eli Lilly

• Project Manager Primary Care

  • May 2004 - Nov 2004

  Implementation of e-projects for blockbuster erectile dysfunction brand CIALIS Implementation of e-projects for blockbuster erectile dysfunction brand CIALIS